CLN-049 Enters a Potentially Registrational AML Study
Cullinan dosed the first participant in a planned potentially registrational Phase 2 study of CLN-049 in relapsed or refractory acute myeloid leukemia. The study uses a brief two-dose optimization phase followed by seamless transition…
